{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:50:45Z","timestamp":1786719045447,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Crit Illn Inj Sci"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijciis.ijciis_15_17","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T01:30:27Z","timestamp":1505179827000},"page":"177","source":"Crossref","is-referenced-by-count":11,"title":["Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma"],"prefix":"10.4103","volume":"7","author":[{"given":"Hamid","family":"Shaaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugabramya","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5151.214403-1","first-page":"180","volume-title":"Opdivo (Nivolumab): Second PD-1 inhibitor receives fda approval for unresectable or metastatic melanoma","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"key-10.4103\/2229-5151.214403-2","first-page":"97","volume-title":"Nivolumab in melanoma: Latest evidence and clinical potential","author":"Johnson","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"key-10.4103\/2229-5151.214403-3","first-page":"368","volume-title":"Checkpoint blocking antibodies in cancer immunotherapy","author":"Kyi","year":"2014","journal-title":"FEBS Lett"},{"key":"key-10.4103\/2229-5151.214403-4","first-page":"905","volume-title":"Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma","author":"Okano","year":"2016","journal-title":"Endocr J"},{"key":"key-10.4103\/2229-5151.214403-5","doi-asserted-by":"crossref","unstructured":"Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep 2016;2016. pii: 16-0108.","DOI":"10.1530\/EDM-16-0108"},{"key":"key-10.4103\/2229-5151.214403-6","first-page":"88","volume-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","author":"Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key-10.4103\/2229-5151.214403-7","first-page":"23","volume-title":"combined nivolumab and ipilimumab or monotherapy in untreated melanoma","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5151.214403-8","first-page":"13","volume-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"key-10.4103\/2229-5151.214403-9","first-page":"122","volume-title":"Nivolumab plus ipilimumab in advanced melanoma","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5151.214403-10","first-page":"1421","volume-title":"Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers","author":"Homet","year":"2015","journal-title":"Br J Cancer"},{"key":"key-10.4103\/2229-5151.214403-11","first-page":"488","volume-title":"Treatment of metastatic melanoma: An overview.Oncology (Williston Park)","author":"Bhatia","year":"2009","journal-title":""},{"key":"key-10.4103\/2229-5151.214403-12","first-page":"886","volume-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Critical Illness and Injury Science"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:43:11Z","timestamp":1786714991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJCIIS.IJCIIS_15_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["214403"],"URL":"https:\/\/doi.org\/10.4103\/ijciis.ijciis_15_17","relation":{},"ISSN":["2229-5151"],"issn-type":[{"value":"2229-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}